Biomarkers that provide an early indicator of kidney stress could be useful in clinical practice to detect silent episodes of acute kidney injury (AKI) or for early identification of subjects at risk of AKI. Two urinary biomarkers have been identified as early indicators of AKI. The NephroCheck® test is a commercially available test that uses these biomarkers, and this study assesses the use of these in reducing negative clinical outcomes for patients with sepsis-associated AKI. The study will enroll subjects diagnosed with sepsis, including septic shock, who will be randomly assigned to either receive NephroCheck®-guided kidney-sparing and fast-tracking interventions; or to receive current Standard of Care assessment and treatment. NOTE: Participants are no longer being recruited to this study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Enrollment
19
NephroCheck® is a device using biomarkers to identify subjects at risk of sepsis-associated acute kidney injury
Standard of Care patient management
LSU Health Sciences Center, 1541 Kings Highway
Shreveport, Louisiana, United States
Brigham and Womens Hospital, 75 Francis Street
Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center, 1275 York Avenue
New York, New York, United States
AZ Sint-Jan Brugge-Oostende, Intensieve Zorgen, Ruddershove 10
Bruges, West-Vlaanderen, Belgium
Hôpital Erasme, Soins Intensifs, Route de Lennik 808
Brussels, Belgium
CHU Angers, 4 Rue Larrey
Angers, Maine-et-Loire, France
Centre Hospitalier de Béthune, Service de Réanimation et Surveillance continue, 27 rue Delbecque
Béthune, Pas-de-Calais, France
CHRU Dijon Complexe Du Bocage, Department Infectiologie, 14 rue Gaffarel
Dijon, France
Hopital Cochin, 27 Rue Du Faubourg Saint Jacques
Paris, France
University Clinic Heidelberg, Klinik für Anaesthesiologie, Im Neuenheimer Feld 110
Heidelberg, Baden-Wurttemberg, Germany
...and 2 more locations
Number of deaths, dialysis or progression of AKI
Measured by composite number of deaths, dialysis or progression of AKI. Dialysis defined as any form of renal replacement therapy (RRT); progression of AKI defined as Stage 0 to 2/3 or Stage 1 to 3.
Time frame: Enrollment to 72 hours
Number of participants with progression of AKI
Progression of AKI (Acute Kidney Injury) to Stage 2 or 3 during the time frame. Measured independently.
Time frame: Enrollment to 48 and 72 hours
Number of deaths
Number of deaths. Measured independently.
Time frame: Enrollment to 48 and 72 hours
Number of participants receiving dialysis
Dialysis defined as any form of renal replacement therapy (RRT). Measured independently.
Time frame: Enrollment to 48 and 72 hours
Number participants at Stage 2 or 3 AKI
Defined as highest stage of AKI during the time frame
Time frame: Enrollment to 72 hours
ICU length of stay
Time frame: Enrollment to hospital discharge or Day 60, whichever is sooner
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.